Protara Therapeutics, Inc.

As of June 30, 2026, Protara Therapeutics, Inc. carries a market capitalization of 200.65M, placing it among publicly traded companies globally. Its enterprise value stands at 78.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Protara Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Protara Therapeutics, Inc. has 59.08M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Protara Therapeutics, Inc. maintains a current ratio of 10.97, meaning it holds 11.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Protara Therapeutics, Inc. posted a negative return on equity (ROE) of -45.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.05, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 46.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Protara Therapeutics, Inc.'s stock has declined approximately 50.32% over the past 52 weeks. The 50-day moving average sits at 2.95, while the 200-day moving average is 3.99.

Over the twelve months ended June 30, 2026, Protara Therapeutics, Inc. generated - - in revenue and converted that into -61.28M in net income, yielding earnings per share of -1.19. EBITDA reached -66.92M, while operating income came in at -67.22M.

As of June 30, 2026, Protara Therapeutics, Inc. holds 124.72M in cash and equivalents against 2.41M in total debt, resulting in a net debt position of -14.95M. Total book value stands at 141.20M, with working capital of 116.27M providing operational flexibility.

Protara Therapeutics, Inc. produced -57.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -315,108.00 in capital expenditures, free cash flow totaled -58.20M - equivalent to -1.13 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -33.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.81, meaning Protara Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Protara Therapeutics, Inc.'s most recent stock split took place on January 13, 2020 with a 40:1 split ratio.

As of June 30, 2026, Protara Therapeutics, Inc. has an Altman Z-Score of 5.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.